Company Interview / Biotron broadens its healthcare scope

Key points:

Biotron Limited (ASX:BIT) acquires Citrix Limited and its anaesthetic technology $2.5 million capital raise supports development and integration of new acquisition Citrix product shows promise for improved safety and cognitive outcomes in anaesthesia Ongoing focus on antiviral pipeline, particularly hepatitis B

Biotron Limited is set to shift its growth outlook with the acquisition of Citrix Limited, a Melbourne-based company developing next generation general anaesthetic agents. Dr Michelle Miller explains that the $2.5 million capital raise led by Peak Asset Management is designed to support this significant new addition to the company’s portfolio. The deal is structured as a share transaction and is viewed as a way to de-risk Biotron’s portfolio for investors while broadening its clinical development scope beyond antivirals.

Miller highlights Citrix’s flagship anaesthetic, which features a reformulated active component previously holding leading market share in the UK. This next-gen agent is combined with an FDA and EMA approved excipient, resulting in recent clinical trial results that indicate lower respiratory and cardiovascular risks compared to existing agents. Notably, Miller points to substantial improvements in post-anaesthesia cognitive function relative to propofol, reducing the cognitive decline often observed in older patients following surgery.

While Biotron continues to see strong opportunity in antiviral development, particularly for hepatitis B, Miller confirms that near-term focus is on advancing the anaesthesia product through regulatory pathways and exploring neurological indications. The capital raise ensures funding for these milestones over the next year, aiming to generate positive shareholder returns before seeking further funding.